Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2score
Key result
Non-vitamin K antagonist oral anticoagulants offer efficacy, safety, and relative convenience compared with vitamin K antagonists for stroke prevention in atrial fibrillation.
Why the study?
Does the SAMe-TT2R2 score help in decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant for stroke prevention in patients with atrial fibrillation?
Population
Patients with atrial fibrillation (AF)
Comparison
Non-vitamin K antagonist oral anticoagulants /… vs Vitamin K antagonists (VKAs, e.g., warfarin)
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
The SAMe-TT2R2 score may assist in clinical decision-making between VKAs and NOACs for stroke prevention in patients with atrial fibrillation.
Key Points
- To review decision-making criteria and clinical scoring tools for choosing between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants in atrial fibrillation management.
- Evaluated the management requirements and quality metrics, including time in therapeutic range (TTR), for vitamin K antagonist therapy.
- Compared the safety, efficacy, and monitoring burdens of non-vitamin K antagonist oral anticoagulants against vitamin K antagonists.
- Maintaining an average individual time in therapeutic range greater than 70% is recommended to maximize the efficacy and safety of vitamin K antagonists.
- Frequent international normalized ratio monitoring remains necessary for vitamin K antagonists due to extensive variability driven by food and drug interactions.
- Non-vitamin K antagonist oral anticoagulants provide clinical efficacy and safety with greater convenience relative to monitored vitamin K antagonist regimens.
Structured PICO
Does the SAMe-TT2R2 score help in decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant for stroke prevention in patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation (AF)
I
Intervention
Non-vitamin K antagonist oral anticoagulants (NOACs) / SAMe-TT2R2 score-guided decision making
C
Comparator
Vitamin K antagonists (VKAs, e.g., warfarin)
The SAMe-TT2R2 score may assist in clinical decision-making between VKAs and NOACs for stroke prevention in patients with atrial fibrillation.
Cite This Study
Proietti et al. (2015) conducted a review in Atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated. Non-vitamin K antagonist oral anticoagulants offer efficacy, safety, and relative convenience compared with vitamin K antagonists for stroke prevention in atrial fibrillation.